PriceTargets.com logo

Anavex Life Sciences - AVXL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.80
  • Forecasted Upside: 379.36%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.72 As of 03/24/2023 01:00 AM ET
▲ +0.04 (0.46%)

This chart shows the closing price for AVXL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anavex Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXL

Analyst Price Target is $41.80
▲ +379.36% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Anavex Life Sciences in the last 3 months. The average price target is $41.80, with a high forecast of $80.00 and a low forecast of $11.00. The average price target represents a 379.36% upside from the last price of $8.72.

This chart shows the closing price for AVXL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Anavex Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2023BTIG ResearchLower TargetBuy$35.00 ➝ $28.00Low
2/6/2023HC WainwrightReiterated RatingBuy$50.00Low
1/3/2023HC WainwrightBoost TargetBuy$42.00 ➝ $50.00Low
12/6/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$16.00 ➝ $11.00Low
12/2/2022JonestradingBoost Target$40.00 ➝ $80.00Low
6/23/2022Berenberg BankInitiated CoverageBuy$40.00Low
3/16/2022HC WainwrightReiterated RatingBuy$42.00High
2/2/2022HC WainwrightBoost TargetBuy$39.00 ➝ $42.00High
11/25/2021BTIG ResearchReiterated RatingBuy$34.00Low
11/19/2021BTIG ResearchReiterated RatingBuy$35.00High
10/14/2021HC WainwrightReiterated RatingBuy$39.00Low
9/23/2021BTIG ResearchInitiated CoverageBuy$35.00High
6/28/2021Cantor FitzgeraldBoost TargetOverweight$31.00 ➝ $40.00High
6/28/2021HC WainwrightReiterated RatingBuy$25.00 ➝ $39.00Low
6/21/2021Dawson JamesBoost TargetBuy$19.00 ➝ $35.00Low
6/15/2021HC WainwrightBoost TargetBuy$17.00 ➝ $25.00High
6/14/2021JonestradingReiterated RatingBuy$35.00High
3/1/2021Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $25.00N/A
2/23/2021Cantor FitzgeraldBoost TargetOverweight$10.00 ➝ $25.00High
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$20.00Low
12/16/2020HC WainwrightBoost TargetPositive ➝ Buy$14.00 ➝ $17.00N/A
10/21/2020HC WainwrightBoost TargetBuy$12.00 ➝ $14.00Low
9/28/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.00High
8/11/2020HC WainwrightReiterated RatingBuyLow
6/16/2020HC WainwrightReiterated RatingBuy$12.00High
6/8/2020Dawson JamesReiterated RatingBuy$16.00Medium
6/8/2020Janney Montgomery ScottReiterated RatingBuy$10.00Medium
6/8/2020Cantor FitzgeraldReiterated RatingBuy$8.00Medium
6/5/2020HC WainwrightReiterated RatingBuy$12.00High
5/22/2020HC WainwrightReiterated RatingBuy$12.00Low
5/8/2020HC WainwrightReiterated RatingBuy$12.00High
4/1/2020HC WainwrightReiterated RatingBuy$12.00High
3/16/2020HC WainwrightInitiated CoverageBuy$12.00Medium
2/26/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
7/24/2019Dawson JamesInitiated CoverageBuy$16.00Low
6/18/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$10.00High
5/23/2019Roth CapitalReiterated RatingBuyMedium
2/8/2019Roth CapitalSet TargetBuy$10.00High
1/28/2019Roth CapitalInitiated CoverageBuy$10.00Low
12/13/2018Maxim GroupSet TargetBuy$7.00High
10/31/2018HC WainwrightSet TargetBuy$10.00Low
10/26/2018Maxim GroupSet TargetBuy$7.00Medium
10/22/2018HC WainwrightReiterated RatingBuy$10.00High
10/19/2018Maxim GroupSet TargetBuy$7.00High
8/28/2018Maxim GroupSet TargetBuy$7.00Low
8/28/2018HC WainwrightSet TargetBuy$10.00Medium
8/10/2018HC WainwrightSet TargetBuy$10.00High
8/9/2018Maxim GroupReiterated RatingBuy$7.00Low
7/25/2018HC WainwrightSet TargetBuy$10.00High
7/10/2018HC WainwrightSet TargetBuy$10.00Low
7/9/2018Maxim GroupInitiated CoverageBuy$7.00Low
7/3/2018Maxim GroupInitiated CoverageBuy$7.00Low
7/3/2018HC WainwrightSet TargetBuy$10.00High
5/31/2018Maxim GroupReiterated RatingBuy$5.00 ➝ $7.00Low
5/30/2018HC WainwrightInitiated CoverageBuy$10.00High
5/16/2018Noble FinancialSet TargetBuy$7.00High
5/16/2018Maxim GroupInitiated CoverageBuy$5.00 ➝ $7.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2023
  • 9 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Anavex Life Sciences logo
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More

Today's Range

Now: $8.72
Low: $8.42
High: $8.79

50 Day Range

MA: $10.11
Low: $8.52
High: $11.75

52 Week Range

Now: $8.72
Low: $7.13
High: $15.24

Volume

1,082,049 shs

Average Volume

1,161,544 shs

Market Capitalization

$680.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Anavex Life Sciences?

The following Wall Street research analysts have issued research reports on Anavex Life Sciences in the last twelve months: Berenberg Bank, BTIG Research, Cantor Fitzgerald, HC Wainwright, Jonestrading, and StockNews.com.
View the latest analyst ratings for AVXL.

What is the current price target for Anavex Life Sciences?

5 Wall Street analysts have set twelve-month price targets for Anavex Life Sciences in the last year. Their average twelve-month price target is $41.80, suggesting a possible upside of 379.4%. Jonestrading has the highest price target set, predicting AVXL will reach $80.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $11.00 for Anavex Life Sciences in the next year.
View the latest price targets for AVXL.

What is the current consensus analyst rating for Anavex Life Sciences?

Anavex Life Sciences currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVXL will outperform the market and that investors should add to their positions of Anavex Life Sciences.
View the latest ratings for AVXL.

What other companies compete with Anavex Life Sciences?

Other companies that are similar to Anavex Life Sciences include Sana Biotechnology, ImmunityBio, Allogene Therapeutics, ADMA Biologics and Exscientia. Learn More about companies similar to Anavex Life Sciences.

How do I contact Anavex Life Sciences' investor relations team?

Anavex Life Sciences' physical mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (844) 689-3939 and its investor relations email address is [email protected] The official website for Anavex Life Sciences is www.anavex.com. Learn More about contacing Anavex Life Sciences investor relations.